New hope for kidney disease? drug combo tested to slow cysts
NCT ID NCT06391450
First seen Jan 04, 2026 · Last updated May 16, 2026 · Updated 22 times
Summary
This study tests the safety of empagliflozin in 44 adults with fast-growing polycystic kidney disease. Some participants also take the standard drug tolvaptan. Researchers measure changes in kidney size and function over 18 months to see if the drug helps slow disease progression.
Disclaimer
Read more
Show less
This is a summary of
the original study
.
Summaries may miss details or leave out important information. Before applying or accepting participation, make sure you have read and understood the full study. Curemydisease.com takes no responsibility whatsoever for anything missed, misunderstood, or acted upon as a result of our summary — we know it does not capture everything.
This is a summary of the original study . Summaries may miss details or leave out important information. Before applying or accepting participation, make sure you have read and understood the full study. Curemydisease.com takes no responsibility whatsoever for anything missed, misunderstood, or acted upon as a result of our summary — we know it does not capture everything.
Get updates
Get notified about this study
Sign up to get updates when this study changes or when new studies for AUTOSOMAL DOMINANT POLYCYSTIC KIDNEY are added.
By submitting, you agree to our Terms of use
Contacts and locations
Show contact details
Enter your email to view the contact information for this study.
By submitting, you agree to our Terms of use
Locations
-
Medizinische Hochschule Hannover
Hanover, Lower Saxony, 30625, Germany
Conditions
Explore the condition pages connected to this study.